Buscar
06/02/2026
Use of anti-nucleocapsid antibody detection as a marker of SARS-CoV-2 infection in healthcare professionals: a longitudinal seroprevalence study at a university hospital in Catalonia, Spain
Micó, M, Trapé, J, González-García, L, Trujillo-Isern, G, González-Fernández, C, López-Madueño, J, Bérgamo, S, Pérez-Vidal, R, Flor, A, Martínez-Montero, R, Rives, J, Arnau, A, Fàbrega, A. Use of anti-nucleocapsid antibody detection as a marker of SARS-CoV-2 infection in healthcare professionals: a longitudinal seroprevalence study at a university hospital in Catalonia, Spain. BMC INFECTIOUS DISEASES. 2026; 26(1)DOI:10.1186/s12879-026-12796-8. PMID:41652586. IF:3.000(Q2/4D).
17/04/2026
N-terminal proBNP adds prognostic value to high-sensitivity cardiac troponin I in elective thoracic surgery: an observational cohort study
Alonso, M, Popova, E, De Miguel, M, García-Osuna, A, Gonzalez-Tallada, A, Ordoñez-Llanos, J, Jauregui, A, Trujillo, JC, Grande, AM, Martínez-Téllez, E, Parera, A, Planas, G, Trujillo, L, Butron, D, Solà-Roca, J, De Nadal, M. N-terminal proBNP adds prognostic value to high-sensitivity cardiac troponin I in elective thoracic surgery: an observational cohort study. BMJ Open. 2026; 16(4)DOI:10.1136/bmjopen-2025-108073. PMID:41997702. IF:2.300(Q2/3D).
07/04/2026
Altered small dense LDL profiles in long-standing controlled type 1 diabetes
Sardà, H, Solé, A, Colom, C, Borràs, C, Carreras, G, Benítez, S, Miñambres, I, Escolà-Gil, JC, Sánchez-Quesada, JL, Pérez, A. Altered small dense LDL profiles in long-standing controlled type 1 diabetes. Frontiers in Endocrinology. 2026; 17DOI:10.3389/fendo.2026.1804987. PMID:42022901. IF:4.600(Q1/3D).
27/04/2026
Why does LDL-C follow a different paradigm from other endocrine-metabolic diseases in cardiovascular prevention?
Sánchez-Quesada, JL, Pérez, A. Why does LDL-C follow a different paradigm from other endocrine-metabolic diseases in cardiovascular prevention?. Frontiers in Endocrinology. 2026; 17DOI:10.3389/fendo.2026.1813342. PMID:42125229. IF:4.600(Q1/3D).
20/01/2026
Cardiovascular biomarkers and preeclampsia: A narrative review
Ullmo, J, Nan, MN, Cruz-Lemini, M, Garrido-Gimenez, C, Platero, J, García-Osuna, A, García-Manau, P, Twickler, M, Llurba, E. Cardiovascular biomarkers and preeclampsia: A narrative review. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2026; 56(1)DOI:10.1111/eci.70123. PMID:41059676. IF:3.600(Q1/2D).
01/10/2024
PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia.
Borràs C, Canyelles M, Girona J, Ibarretxe D, Santos D, Revilla G, Llorente-Cortes V, Rotllan N, Kovanen PT, Jauhiainen M, Lee-Rueckert M, Masana L, Arrieta F, Martínez-Botas J, Gómez-Coronado D, Ribalta J, Tondo M, Blanco-Vaca F, Escolà-Gil JC. PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia.. Jacc-Basic To Translational Science. 2024; 9(10)DOI:10.1016/j.jacbts.2024.06.008. PMID:39534644. IF:(Q/D).
01/08/2024
Exploring Plasma Coenzyme Q10 Status in Paediatric Dyslipidaemia
Minguez, B, de Los Santos, M, Garcia-Volpe, C, Molera, C, Paredes-Fuentes, AJ, Oliva, C, Arias, A, Rodriguez-Gonzalez, H, Yubero, D, Tondo, M, Santos-Ocaña, C, Meavilla, S, Artuch, R. Exploring Plasma Coenzyme Q10 Status in Paediatric Dyslipidaemia. Antioxidants. 2024; 13(8)DOI:10.3390/antiox13080966. PMID:39199213. IF:6.600(Q1/1D).
01/05/2026
Effects of zibotentan and dapagliflozin combined in patients with compensated cirrhosis: A randomized placebo-controlled exploratory study
Garcia-Pagan, JC, Gluud, LL, Mandorfer, M, Schattenberg, JM, De Gottardi, A, Berzigotti, A, Fortea, JI, Martínez, AA, Alvarado-Tapias, E, Berning, M, Petryszyn, P, Henricson, E, Berglind, N, Lin, M, Persson, K, Mercier, A, Ambery, P, Bosch, J, Oscarsson, J, Rockey, DC. Effects of zibotentan and dapagliflozin combined in patients with compensated cirrhosis: A randomized placebo-controlled exploratory study. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2026; 92(5)DOI:10.1002/bcp.70332. PMID:41362018. IF:3.000(Q2/4D).